Nikon was among the investors that helped the eye disease treatment developer close a round that pushed its overall funding to $24m.
US-based ophthalmic medical device developer LumiThera closed a $14m series C round that included optics technology manufacturer Nikon Corporation yesterday.
Investment firm WaterStar Capital led the round, which also featured Celeste Management, Imagine Ventures, Keiretsu Capital and Water Star Mercury Fund.
Founded in 2013, LumiThera is developing Valeda Light Delivery System, a non-invasive treatment for age-related macular degeneration (AMD), a condition that causes eye diseases and blindness.
Clark Tedford, LumiThera’s president and CEO, said: “Our soft launch in Europe in…
